Ceredex Value Advisors LLC Has $8.83 Million Position in Bruker Corporation $BRKR

Ceredex Value Advisors LLC cut its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 23.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 214,250 shares of the medical research company’s stock after selling 65,050 shares during the quarter. Ceredex Value Advisors LLC owned approximately 0.14% of Bruker worth $8,827,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nisa Investment Advisors LLC raised its holdings in shares of Bruker by 377.5% during the second quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 487 shares during the period. Huntington National Bank raised its stake in Bruker by 750.0% during the 2nd quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock worth $30,000 after buying an additional 645 shares during the period. Spire Wealth Management bought a new position in Bruker in the second quarter worth approximately $32,000. Caitong International Asset Management Co. Ltd grew its stake in Bruker by 1,354.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 745 shares during the period. Finally, Parallel Advisors LLC increased its holdings in shares of Bruker by 63.0% during the second quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 347 shares in the last quarter. 79.52% of the stock is owned by institutional investors.

Bruker Stock Performance

NASDAQ BRKR opened at $47.75 on Friday. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. The company has a fifty day moving average price of $38.89 and a 200-day moving average price of $37.62. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $64.64. The firm has a market cap of $7.26 billion, a price-to-earnings ratio of 91.83, a PEG ratio of 5.31 and a beta of 1.26.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.12. The business had revenue of $860.50 million for the quarter, compared to analysts’ expectations of $847.40 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The firm’s revenue for the quarter was down .5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.60 earnings per share. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, equities research analysts predict that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Shareholders of record on Monday, December 8th will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, December 8th. Bruker’s dividend payout ratio is -125.00%.

Insider Buying and Selling at Bruker

In related news, Director Cynthia M. Friend sold 3,535 shares of the stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $32.25, for a total transaction of $114,003.75. Following the completion of the transaction, the director owned 18,016 shares in the company, valued at approximately $581,016. This represents a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John A. Ornell sold 6,233 shares of Bruker stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $39.00, for a total transaction of $243,087.00. Following the completion of the sale, the director directly owned 35,212 shares in the company, valued at approximately $1,373,268. This represents a 15.04% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 27.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on BRKR. Redburn Partners set a $60.00 target price on Bruker in a report on Thursday, November 20th. TD Cowen upped their price objective on shares of Bruker from $40.00 to $42.00 and gave the stock a “hold” rating in a report on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Bruker in a research note on Tuesday. UBS Group boosted their target price on shares of Bruker from $40.00 to $43.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Finally, Rothschild & Co Redburn initiated coverage on shares of Bruker in a research report on Thursday, November 20th. They issued a “buy” rating and a $60.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $50.25.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.